To our knowledge, this is the first study evaluating the diagnostic utility of serum CXCL1 and CXCR1 in CRC patients in relation to the well-established tumor biomarker (CEA) and the marker of inflammation (CRP). The gene discussed is CXCR1; the disease is neoplasm.